drugset / Trial / NCT00880789

Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus

NCT00880789 ↗

NaSingle-groupOpen-labelTreatment

Summary

With this study, we want to see if we can use a kind of white blood cell called T cells to prevent or treat AdV and CMV infection. We will grow these T cells from the cord blood before the patients transplant. These cells have been trained to attack adenovirus/CMV-infected cells and are called Adenoviral/CMV-specific cytotoxic (killer) T-cells or "AdV/CMV-CTL." We would plan to give the patient one dose of AdV/CMV-CTL any time from 30 days after their transplant. We have used T cells made in this way from the blood of donors to prevent infections in patients who are getting a bone marrow or blood stem cell transplant but this will be the first time we make them from cord blood.

Timeline

Start
2009-05
Primary completion
2013-08
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CMV/AdV specific T cells Cell therapy 5e+06 unknown Intravenous